Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPSMA: AAA602 and AAA802 in High-Risk Localized Prostate Cancer
NCT06881823Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Mar 2030
- Modality
- Small Molecules, Peptide-Drug Conjugates
01
Overview
Phase 2, randomised, open-label trial of lutetium lu-177 psma-r2 and 225Ac-PSMA-R2 in prostate cancer (PCa), sponsored by Novartis. Primary endpoints: Number of participants with dose-limiting toxicities at 6 weeks and Biochemical recurrence free survival at 60 months. Planned start Jun 2026; status: withdrawn.
02
Drugs
lutetium lu-177 psma-r2225Ac-PSMA-R2
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06881823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881823.